Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Carcinogenesis|November 28, 2013
Secretory leukocyte protease inhibitor modulates urethane-induced lung carcinogenesisCezary Jan Treda, Tatsuro Fukuhara, Takuji Suzuki, et al.
Canadian Respiratory Journal|August 2, 2016
EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp MethodKana Watanabe, Tatsuro Fukuhara, Yoko Tsukita, et al.
Cancer Science|September 21, 2021
MK-6, a novel not-α IL-2, elicits a potent antitumor activity by improving the effector to regulatory T cell balanceMaki Kobayashi, Katsuhiko Kojima, Kazutaka Murayama, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2006
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutationsAkira Inoue, Takuji Suzuki, Tatsuro Fukuhara, et al.
Internal Medicine (Tokyo, Japan)|December 16, 2015
Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung AdenocarcinomaYoko Tsukita, Tatsuro Fukuhara, Maki Kobayashi, et al.
Cancer Science|August 30, 2008
Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammationAkira Inoue, Hong Xin, Takuji Suzuki, et al.
Cancers|September 9, 2023
Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M MutationKana Watanabe, Ryota Saito, Eisaku Miyauchi, et al.
The Journal of Biological Chemistry|October 27, 2004
Involvement of the c-Src-Crk-C3G-Rap1 signaling in the nectin-induced activation of Cdc42 and formation of adherens junctionsTaihei Fukuyama, Hisakazu Ogita, Tomomi Kawakatsu, et al.
The Journal of Cell Biology|July 28, 2004
Activation of Cdc42 by trans interactions of the cell adhesion molecules nectins through c-Src and Cdc42-GEF FRGTatsuro Fukuhara, Kazuya Shimizu, Tomomi Kawakatsu, et al.
Respiratory Investigation|April 9, 2013
Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703Nobumichi Matsubara, Makoto Maemondo, Akira Inoue, et al.
Pageof 5